The “Studienstandort-Barometer” is a newly launched tool developed by Vintura in collaboration with the German Association of Research-Based Pharmaceutical Companies (vfa) and the Federal Association of Contract Research Organizations (BVMA). Its purpose is to measure Germany’s attractiveness for conducting clinical trials and to track how this evolves over time.
The first results are in, and while they reflect a moderate current state, they also reveal cautious optimism among pharmaceutical companies and clinical research organizations. Many expect an increase in clinical trial activity over the next twelve months. This sentiment is shaped by recent regulatory improvements, including faster approval processes and incentives for recruiting trial participants within Germany.
What makes the barometer particularly valuable is its ability to capture early signals from the field. Clinical research organizations, for example, often notice shifts in demand before broader trends become visible. Their input adds sensitivity to the tool and helps paint a more accurate picture of the clinical trial environment.
The next update, planned for early 2026, will be especially telling. Several reforms introduced through the 2024 Medical Research Act will only take full effect in December. Among them are standardized contract clauses that could significantly speed up negotiations for trial participation. If these changes deliver as expected, Germany may soon regain ground in the international competition for clinical research.
Stay informed and be part of the conversation.
Whether you’re a sponsor, clinical research organization, investigator, or policymaker, understanding the dynamics of Germany’s clinical trial landscape is essential. Click through to see the data, and join the effort to shape a more competitive and research-friendly environment. If you would like to discuss then you’re welcome to connect with Jan-Philipp Beck and Ann-Sophie Kuschel for further insights
